Merck KGaA Darmstadt Germany - Rahway, NJ
posted 2 months ago
The Director, US Pharma Payer Marketing Atherosclerosis leads a dedicated team of payer marketers focused on developing access strategies and tactics for a macrocyclic peptide drug, which is an investigational novel treatment aimed at reducing LDL levels in adults with hypercholesterolemia. This drug is currently in Phase 3 Clinical Development. The Director will collaborate closely with the US Commercial Leader and the associated brand Customer Agile teams to formulate value evidence strategies and tactics, leveraging insights from data & analytics, Integrated Account Management, Outcomes Research, and other stakeholder groups. This role is pivotal in ensuring that the marketing strategies align with the overall business objectives and market needs. As a member of the Payer Marketing leadership team, the Director will report directly to the US Pharma Payer Marketing Lead and will actively participate in all brand and business reviews. The Director will also serve as a subject matter expert on the US healthcare ecosystem, understanding the interconnectivity of private and public payors, hospital delivery systems, and policy trends relevant to the US Pharma portfolio throughout its lifecycle. Additionally, the Director will oversee pricing strategies and represent US Pharma in market-level pricing discussions, ensuring that the company’s products are positioned effectively in the market. Key responsibilities include working closely with US commercial leaders to inform access strategy planning, developing a high-performing team of payer marketing associate directors through competency development and coaching, and collaborating with Integrated Account Management leadership and account executives to incorporate customer and market insights into the implementation of customer programs. The Director will also be involved in the development of value evidence strategies, addressing implications and opportunities associated with critical policy issues, and supporting commercial assessments related to access and pricing for pipeline and business development assets.